# Challenges of Wearable Biosensors and Ways to Overcome Them

**Authors:** Sergei Tarasov, Yulia Plekhanova, Anatoly Reshetilov, Sergey Melenkov, Ivan Saltanov

PMC · DOI: 10.3390/bios16030159 · Biosensors · 2026-03-13

## TL;DR

Wearable biosensors are transforming healthcare by enabling personalized medicine, but their widespread use faces challenges like standardization and security.

## Contribution

This review identifies current challenges in wearable biosensors and proposes solutions, focusing on continuous glucose monitoring devices.

## Key findings

- Wearable biosensors enable real-time biomarker tracking for personalized healthcare.
- Challenges include standardization, data security, and risks of immune responses or infections.
- Continuous glucose monitoring is a successful example but still requires improvements for large-scale adoption.

## Abstract

In the 21st century, there have been radical changes in healthcare related to the transition from a universal approach to personalized medicine based on the unique characteristics of each patient. In large part, this has become possible due to the development and distribution of wearable medical devices that are capable of providing continuous monitoring of a variety of physiological parameters outside medical institutions. The most important of these devices are modern biosensors that allow real-time tracking of various biomarkers in the body, thereby opening up new opportunities for disease prevention, early diagnosis, and personalized treatment strategies. The most obvious example of the transformation is the implementation of wearable devices for continuous glucose monitoring (CGM), which has significantly facilitated the daily lives of millions of people with diabetes. Nevertheless, despite the examples of successful implementation of these devices, their large-scale distribution is associated with many challenges, such as the need for standardization, data transmission security, and the risks of immune responses to implantable devices or infections. This review examines all the current problems of wearable biosensors and possible ways to overcome them. Special emphasis will be placed on devices for continuous glucose monitoring as the most commercially successful representatives of this device class.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** sepsis (MESH:D018805), neurological injuries (MESH:D020196), obesity (MESH:D009765), Crohn's disease (MESH:D003424), cancer (MESH:D009369), contact dermatitis (MESH:D003877), tissue injury (MESH:D017695), ulcerative colitis (MESH:D003093), sickle cell anemia (MESH:D000755), oral diseases (MESH:D009059), itching (MESH:D011537), stroke (MESH:D020521), neonatal jaundice (MESH:D007567), infection (MESH:D007239), injury to (MESH:D014947), lactic acidosis (MESH:D000140), dermatitis (MESH:D003872), subarachnoid hemorrhage (MESH:D013345), protein-losing enteropathy (MESH:D011504), diabetic ketoacidosis (MESH:D016883), traumatic brain injury (MESH:D000070642), diabetes (MESH:D003920), gastrointestinal disorders (MESH:D005767), celiac disease (MESH:D002446), inflammation (MESH:D007249), neurodegenerative and mental disorders (MESH:D019636), skin irritation (MESH:D012871), allergic reactions (MESH:D004342), hypoglycemia (MESH:D007003), allergic contact dermatitis (MESH:D017449), problems (MESH:D019973), type 1 diabetes (MESH:D003922), high blood pressure (MESH:D006973), hypoxic (MESH:D002534), toxicity (MESH:D064420), cardiovascular diseases (MESH:D002318), hyperglycemia (MESH:D006943), pain (MESH:D010146), irritation (MESH:D001523)
- **Chemicals:** PVA (MESH:D011142), O2 (MESH:D010100), hydrogen peroxide (MESH:D006861), bilirubin (MESH:D001663), lactate (MESH:D019344), rosin (MESH:C013893), salts (MESH:D012492), carbon (MESH:D002244), oil (MESH:D009821), blood glucose (MESH:D001786), PDMS (MESH:C013830), aspirin (MESH:D001241), acetaminophen glucuronide (MESH:C037386), Polyethylene glycol (MESH:D011092), cortisol (MESH:D006854), Paracetamol (MESH:D000082), Na+ (MESH:D012964), serotonin (MESH:D012701), PET (MESH:D011093), silicone (MESH:D012828), polymer (MESH:D011108), GOx (-), CRB (MESH:C048653), agarose (MESH:D012685), uric acid (MESH:D014527), PEGDA (MESH:C437167), Prinivil (MESH:D017706), L-Dopa (MESH:D007980), K+ (MESH:D011188), dopamine (MESH:D004298), ketones (MESH:D007659), polyacrylamide (MESH:C016679), water (MESH:D014867), Ag (MESH:D012834), glycerol (MESH:D005990), Prussian Blue (MESH:C000170), triethylene glycol (MESH:C028914), Cu (MESH:D003300), Glucose (MESH:D005947), graphene (MESH:D006108), polyester (MESH:D011091), hydroxyurea (MESH:D006918), ZnO (MESH:D015034), cellulose (MESH:D002482), salicylate (MESH:D012459), alcohol (MESH:D000438), titanium (MESH:D014025), ascorbic acid (MESH:D001205), acrylates (MESH:D000179), CO2 (MESH:D002245), PEDOT:PSS (MESH:C533756), lithium (MESH:D008094), steroids (MESH:D013256), 1.10-Phenanthroline-5.6-dione (MESH:C037153), acrylate (MESH:C036658)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13024049/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13024049/full.md

## References

314 references — full list in the complete paper: https://tomesphere.com/paper/PMC13024049/full.md

---
Source: https://tomesphere.com/paper/PMC13024049